Screening for allergic respiratory disease in the general population with the ADVIA Centaur® Allergy Screen Assay
Screening for allergic respiratory disease in the general population with the ADVIA Centaur® Allergy Screen Assay
复制标题
DOI：
10.1111/j.1398-9995.2006.00968.x
复制
发表时间：
2006-03-01
期刊：
影响因子：
12.4
通讯作者：
Johansen, N
中科院分区：
文献类型：
--
作者：
Linneberg, A;Husemoen, LLN;Johansen, N
背景资料：在免疫球蛋白E（IgE）介导的过敏性呼吸道疾病的临床指征较弱的患者中，针对多种过敏原特异性的IgE抗体的单一定性多过敏原筛查试验可能支持不存在IgE介导的过敏性呼吸道疾病。目的是探讨一种新的多变应原筛查检测的诊断效果与皮肤点刺试验（SPT）的反应性和过敏性呼吸道疾病的客观诊断在一般人群setting.Methods：共709名参与者在一项以人群为基础的研究进行了调查问卷和SPT。通过使用多变应原筛选试验：ADVIA Centaur（（R））Allergy Screen（AS）试验分析血清。AS检测的二分法结果与SPT反应性，特异性IgE阳性，过敏性鼻炎或过敏性哮喘的临床诊断定义的存在下，相关症状和阳性SPTs.Results：敏感性，特异性，阳性（PPV）和阴性预测值（NPV）的AS对SPT反应性分别为86%，96%，94%和89%，分别。阴性AS检测能够排除过敏性鼻炎和过敏性哮喘，其概率分别超过96%和98%（NPV）。AS检测能够识别超过92%和92%（敏感性）的过敏性鼻炎和过敏性asthma，respectively.Conclusions：AS检测被证明是一个有效的措施过敏性呼吸道疾病，可用作筛选工具，以排除过敏性呼吸道疾病，并作为一个客观的措施过敏性呼吸道疾病的流行病学研究。
Background: In patients in whom the clinical indication for immunoglobulin E (IgE)-mediated allergic respiratory disease is weak, a single qualitative multiallergen-screening assay for IgE antibody to multiple allergen specificities may support the absence of IgE-mediated allergic respiratory disease. The aim was to investigate the diagnostic efficacy of a new multiallergen-screening assay in relation to skin prick test (SPT) reactivity and objective diagnoses of allergic respiratory disease in a general population setting.Methods: A total of 709 participants in a population-based study were examined by questionnaire and SPT. Serum was analysed by using a multiallergen-screening assay: the ADVIA Centaur((R)) Allergy Screen (AS) assay. The dichotomized result of the AS assay was compared with SPT reactivity, specific IgE positivity, and a clinical diagnosis of allergic rhinitis or allergic asthma defined by the presence of relevant symptoms and positive SPTs.Results: Sensitivity, specificity, and positive (PPV) and negative predictive values (NPV) of the AS against SPT reactivity were 86%, 96%, 94%, and 89%, respectively. A negative AS assay test was able to exclude allergic rhinitis and allergic asthma with a probability of more than 96% and 98% (NPV), respectively. The AS assay was able to identify more than 92% and 92% (sensitivity) of cases of allergic rhinitis and allergic asthma, respectively.Conclusions: The AS assay proved to be a valid measure of allergic respiratory disease and may be used as a screening tool to rule out allergic respiratory disease, and as an objective measure of allergic respiratory disease in epidemiological studies.